Detailed narrative
Four converging companion-animal dynamics behind the miss
Management framed the quarter as unfolding differently than expected due to interconnected point-of-care dynamics: veterinary clinic pricing kept rising (though at a slower pace) on top of multi-year increases, pressuring clinic traffic; pet owners showed increased price sensitivity with softer demand for premium preventative and chronic-care products where Zoetis leads; competition intensified across dermatology, parasiticides and vaccines with more entrants across more markets leaning on aggressive pricing and incentives for extended periods; and — in contrast to history — these new entrants did not expand the overall market.
Winter storms further reduced clinic visits. As the share leader in premium categories, Zoetis was disproportionately exposed versus entrants competing primarily on price, at a point in its cycle where growth is less driven by new product launches until the blockbuster pipeline arrives.
Fiscal-year alignment mechanics and comparability
Q1 FY26 is the first quarter presented on an aligned calendar year for non-U.S. subsidiaries, with recast 2025 quarterly and 2024–2025 annual figures posted as supplemental materials. Recast Q4 2025 revenue is $128M lower than previously reported: roughly $30M reflected accelerated sales timing recognized in the International segment in Q4 2025, and the remaining ~$100M shifted into Q1 2026 International sales, driven by changed timing of📎 price increases in certain international markets, delayed processing of customer orders, and business-performance differences versus a stronger Q4 2024.
Most other quarters' recast differences are relatively immaterial. Excluding the ~$100M shift, both global revenue and International segment growth look materially weaker than the headline print.
Dermatology and parasiticides under price-led competitive pressure
Apoquel faces intensified global competition where price has become the primary differentiator, with impact more pronounced than management expected and share loss amplified by a derm market with declining patient volume in clinics — without the market-expansion cushion of prior competitive cycles, though management sees a path back to growth given significant untreated and undertreated dogs.
Cytopoint is holding up better, affected mainly by clinic-visit dynamics as a longer-duration monoclonal antibody, with low switching to recent JAKi competitors. In U.S. parasiticides, competitive launches from earlier in 2025 pressured share largely through aggressive promotion, but share stabilized with levels nearing prior year by quarter end and puppy share remaining well above overall patient share; the triple-combination market is no longer expanding the way it did during the prior competitive launch wave, and flea/tick/heartworm clinic visits declined.
OA Pain: stabilization plus franchise expansion
Librela drove the year-over-year OA decline but has stabilized in the U.S. with roughly flat sequential growth — the first sequential U.S. revenue increase in six quarters — reflecting a multipronged strategy emphasizing medical education and specialist engagement to build prescribing confidence.
Findings published by the U.K. Veterinary Medicines Directorate confirming Librela's positive benefit-risk profile improved conversations with vets in that market, and additional label updates are expected as a normal part of ongoing regulatory review. Solensia continued to perform well with feline OA visits roughly flat.
Lenivia and Portela are in early launch phases in certain European markets and Canada — management stressed Lenivia is not simply long-acting Librela — with encouraging early feedback, expanding the franchise around convenience and affordability.
Livestock and diagnostics carry the quarter
Livestock delivered broad-based growth across geographies and species on favorable producer economics, sustained protein demand, disease outbreaks driving vaccine adoption, improved product supply and commercial wins. U.S. cattle benefited from improved Septicure supply and strong spring-promotion demand; poultry from increased vaccine adoption amid outbreaks; swine from improved supply; and fish from improved Moritella vaccine pricing plus market expansion into the Faroe Islands.
The portfolio is more focused following the MFA divestiture. Diagnostics strength came from reference-lab expansion, chemistry and hematology (Vetscan Opticell), and continued progress in imaging, consistent with pet spending remaining resilient in urgent and diagnostic care even as preventative/chronic premium categories soften.
U.S. channel dynamics: destocking and retail friction
Distributors historically enter Q1 with elevated inventories after buying ahead of price increases and promotions. This quarter promotions underperformed expectations and end-market demand softened, so distributors and retail partners worked through opening inventories longer and replenished less — sales into the channel lagged sales out to customers versus prior-year quarters.
Management characterized quarter-end channel inventory as normalized rather than a continuing headwind, is not assuming any inventory rebound in guidance (echoing the post-2023 structural step-down in distributor stocking), and noted retail is still growing faster than the clinic but at a sharply slower rate, partly due to script denials in the retail channel.
Response plan: execution, cost discipline, and targeted BD
The action plan spans four fronts. Commercially: integrated portfolio solutions for veterinarians that strengthen clinic economics, localized action plans in priority markets, targeted DTC investment, simplified point-of-sale choices with loyalty and affordability options (shifting from scan-and-cashback-later to point-of-sale relief), and convenient authorized access across clinic, retail and home delivery, plus supply continuity in livestock.
Innovation: accelerating the science-to-scale model to shorten approval-to-launch time, prioritizing near-term launches and convenience-led life-cycle innovations including long-acting mAbs, Procerta and Convenia RTU. Portfolio: the Neogen animal-genomics acquisition exemplifies incremental, targeted BD — management explicitly ruled out large transformational deals.
Capital/costs: a comprehensive cost and productivity program tightening discretionary spend, procurement and organizational levers. Management is also leveraging AI across discovery, research, development and dossier preparation, and partnering with the FDA on faster innovation pathways.